Memory B cells are a more reliable archive for historical antimalarial responses than plasma antibodies in no-longer exposed children

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 21, 2012, Pages 8247-8252

  Ndungu, Francis Maina ^a,b   Olotu, Ally ^a   Mwacharo, Jedidah ^a   Nyonda, Mary ^a   Apfeld, Jordan ^a   Mramba, Lazarus K ^a   Fegan, Gregory W ^a,c   Bejon, Philip ^a,d   Marsh, Kevin ^a,b  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Immunity; Immunological; Longevity; Maintenance; Protection

Indexed keywords

IMMUNOGLOBULIN G; MEROZOITE SURFACE PROTEIN 1; PARASITE ANTIGEN; RECOMBINANT ANTIGEN;

ADOLESCENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; BLOOD SMEAR; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; ENDEMIC DISEASE; ENVIRONMENTAL EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MEMORY CELL; PARASITEMIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROLOGY; SEROPREVALENCE;

ADOLESCENT; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; B-LYMPHOCYTES; BIOLOGICAL SPECIMEN BANKS; CHILD; CHILD, PRESCHOOL; ENDEMIC DISEASES; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; INFANT; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES;

PLASMODIUM FALCIPARUM;

EID: 84861444790     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1200472109     Document Type: Article

References (55)

1. Mendis K, et al. (2009) From malaria control to eradication: The WHO perspective. Trop Med Int Health 14:802-809.
2. Nájera JA (2001) Malaria control: Achievements, problems and strategies. Parassitologia 43:1-89.
3. Ceesay SJ, et al. (2008) Changes in malaria indices between 1999 and 2007 in The Gambia: A retrospective analysis. Lancet 372:1545-1554.
4. O'Meara WP, et al. (2009) The impact of primary health care on malaria morbidity - Defining access by disease burden. Trop Med Int Health 14:29-35.
5. Okiro EA, et al. (2007) The decline in paediatric malaria admissions on the coast of Kenya. Malar J 6:151.
6. Ceesay SJ, et al. (2010) Continued decline of malaria in The Gambia with implications for elimination. PLoS ONE 5:e12242.
7. Langhorne J, Ndungu FM, Sponaas AM, Marsh K (2008) Immunity to malaria: More questions than answers. Nat Immunol 9:725-732.
8. Marsh K (1992) Malaria - A neglected disease? Parasitology 104(Suppl):S53-S69.
9. Marsh K, Kinyanjui S (2006) Immune effector mechanisms in malaria. Parasite Immunol 28:51-60.
10. Ghani AC, et al. (2009) Loss of population levels of immunity to malaria as a result of exposure-reducing interventions: Consequences for interpretation of disease trends. PLoS ONE 4:e4383.
11. Bejon P, Ogada E, Peshu N, Marsh K (2009) Interactions between age and ITN use determine the risk of febrile malaria in children. PLoS ONE 4:e8321.
12. Aponte JJ, et al. (2007) Age interaction in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. PLoS Med 4:e242.
13. Kleinschmidt I, et al. (2009) Marked increase in child survival after four years of intensive malaria control. Am J Trop Med Hyg 80:882-888.
14. Cohen S, McGREGOR IA, Carrington S (1961) Gamma-globulin and acquired immunity to human malaria. Nature 192:733-737.
15. Fowkes FJ, Richards JS, Simpson JA, Beeson JG (2010) The relationship between antimerozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med 7:e1000218.
16. Sabchareon A, et al. (1991) Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 45:297-308.
17. Akpogheneta OJ, et al. (2008) Duration of naturally acquired antibody responses to blood-stage Plasmodium falciparum is age dependent and antigen specific. Infect Immun 76:1748-1755.
18. Cavanagh DR, et al. (1998) A longitudinal study of type-specific antibody responses to Plasmodium falciparum merozoite surface protein-1 in an area of unstable malaria in Sudan. J Immunol 161:347-359.
19. Kinyanjui SM, Bull P, Newbold CI, Marsh K (2003) Kinetics of antibody responses to Plasmodium falciparum-infected erythrocyte variant surface antigens. J Infect Dis 187:667-674.
20. Drakeley CJ, et al. (2005) Altitude-dependent and -independent variations in Plasmodium falciparum prevalence in northeastern Tanzania. J Infect Dis 191:1589-1598.
21. Taylor RR, et al. (1996) Selective recognition of malaria antigens by human serum antibodies is not genetically determined but demonstrates some features of clonal imprinting. Int Immunol 8:905-915.
22. Bernasconi NL, Traggiai E, Lanzavecchia A (2002) Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298:2199-2202.
23. Böttiger M, Gustavsson O, Svensson A (1998) Immunity to tetanus, diphtheria and poliomyelitis in the adult population of Sweden in 1991. Int J Epidemiol 27:916-925.
24. Crotty S, Ahmed R (2004) Immunological memory in humans. Semin Immunol 16:197-203.
25. Crotty S, et al. (2003) Cutting edge: Long-term B cell memory in humans after smallpox vaccination. J Immunol 171:4969-4973.
26. Banatvala J, Van Damme P, Oehen S (2000) Lifelong protection against hepatitis B: The role of vaccine immunogenicity in immune memory. Vaccine 19:877-885.
27. Bauer T, Jilg W (2006) Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 24:572-577.
28. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ (1997) Protection provided by hepatitis B vaccine in a Yupik Eskimo population - Results of a 10-year study. J Infect Dis 175:674-677.
29. West DJ, Calandra GB (1996) Vaccine induced immunologic memory for hepatitis B surface antigen: Implications for policy on booster vaccination. Vaccine 14:1019-1027.
30. Jilg W, Schmidt M, Deinhardt F (1990) Decline of anti-HBs after hepatitis B vaccination and timing of revaccination. Lancet 335:173-174.
31. Vande Waa JA, Jensen JB, Akood MA, Bayoumi R (1984) Longitudinal study on the in vitro immune response to Plasmodium falciparum in Sudan. Infect Immun 45:505-510.
32. Migot F, et al. (1993) Human immune responses to the Plasmodium falciparum ring-infected erythrocyte surface antigen (Pf155/RESA) after a decrease in malaria transmission in Madagascar. Am J Trop Med Hyg 48:432-439.
33. Crompton PD, et al. (2009) The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. J Immunol 182:3318-3326.
34. Nogaro SI, et al. (2011) The breadth, but not the magnitude, of circulating memory B cell responses to P. falciparum increases with age/exposure in an area of low transmission. PLoS ONE 6:e25582.
35. Weiss GE, et al. (2012) High efficiency human memory B cell assay and its application to studying Plasmodium falciparum-specific memory B cells in natural infections. J Immunol Methods 375:68-74.
36. Weiss GE, et al. (2010) The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections. PLoS Pathog 6:e1000912.
37. Wipasa J, et al. (2010) Long-lived antibody and B Cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. PLoS Pathog 6:e1000770.
38. Mwangi TW, Mohammed M, Dayo H, Snow RW, Marsh K (2005) Clinical algorithms for malaria diagnosis lack utility among people of different age groups. Trop Med Int Health 10:530-536.
39. Mwangi TW, Ross A, Snow RW, Marsh K (2005) Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. J Infect Dis 191:1932-1939.
40. Pierce SK (2009) Understanding B cell activation: From single molecule tracking, through Tolls, to stalking memory in malaria. Immunol Res 43:85-97.
41. Struik SS, Riley EM (2004) Does malaria suffer from lack of memory? Immunol Rev 201:268-290.
42. Radbruch A, et al. (2006) Competence and competition: The challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6:741-750.
43. Combe A, et al. (2009) Clonal conditional mutagenesis in malaria parasites. Cell Host Microbe 5:386-396.
44. Osier FH, et al. (2008) Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun 76:2240-2248.
45. Mackintosh CL, et al. (2008) Failure to respond to the surface of Plasmodium falciparum infected erythrocytes predicts susceptibility to clinical malaria amongst African children. Int J Parasitol 38:1445-1454.
46. Bejon P, et al. (2009) Immunity to febrile malaria in children: An analysis that distinguishes immunity from lack of exposure. Infect Immun 77:1917-1923.
47. Smith T, Felger I, Tanner M, Beck HP (1999) Premunition in Plasmodium falciparum infection: Insights from the epidemiology of multiple infections. Trans R Soc Trop Med Hyg 93(Suppl 1):59-64.
48. Migot F, et al. (1995) Anti-malaria antibody-producing B cell frequencies in adults after a Plasmodium falciparum outbreak in Madagascar. Clin Exp Immunol 102:529-534.
49. Bejon P, et al. (2007) The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum. J Immunol 179:4193-4201.
50. Mbogo CM, et al. (2003) Spatial and temporal heterogeneity of Anopheles mosquitoes and Plasmodium falciparum transmission along the Kenyan coast. Am J Trop Med Hyg 68:734-742.
51. Mbogo CN, et al. (1995) Relationships between Plasmodium falciparum transmission by vector populations and the incidence of severe disease at nine sites on the Kenyan coast. Am J Trop Med Hyg 52:201-206.
52. Polley SD, et al. (2006) High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Vaccine 24:4233-4246.
53. Polley SD, et al. (2004) Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 23:718-728.
54. Polley SD, et al. (2007) Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. J Infect Dis 195:279-287.
55. Rougemont M, et al. (2004) Detection of four Plasmodium species in blood from humans by 18S rRNA gene subunit-based and species-specific real-time PCR assays. J Clin Microbiol 42:5636-5643.